Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

RYTM - Rhythm Pharmaceuticals, Inc. So'nggi... | Finranks

Home

/

RYTM

R

Rhythm Pharmaceuticals, Inc. (RYTM)

NGM – Real vaqt narxi. Valyuta: USD

117.60

+4.75 (4.21%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

117.60

0.00 (0.00%)

Bozordan keyin: Aug 12, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences.

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

Rhythm Pharmaceuticals Q2 Earnings Call Highlights

Rhythm Pharmaceuticals Q2 Earnings Call Highlights

Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.75 per share a year ago.

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition

Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body weight in patients with a rare form of obesity caused by damage to the brain, ‌according to preliminary data from an ongoing mid-stage study.

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product revenue from global sales of IMCIVREE of $71.3 million -- -- Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO (n=7) after 16 weeks of treatment -- -- Phase 3 TRANSCEND Trial Results in Acquired HO published in the New England Journal of Medicine -- -- Management to host conference call today at 8:00 a.m. ET --

Videolar

No Data

There is no data to display

Press-relizlar

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product revenue from global sales of IMCIVREE of $71.3 million -- -- Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO (n=7) after 16 weeks of treatment -- -- Phase 3 TRANSCEND Trial Results in Acquired HO published in the New England Journal of Medicine -- -- Management to host conference call today at 8:00 a.m. ET --

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon --